TL;DR
The October 2026 Clinical Laboratory Fee Schedule (26CLABQ4) lists 2,243 code and modifier rows for 2,117 laboratory test codes: 2,125 rows carry a national payment amount and 118 are priced locally by the Medicare Administrative Contractor. National amounts for the base codes run from $2.17 to $12,000.00 with a median of $35.09. The file adds 40 rows since the July release, all of them proprietary laboratory analyses (PLA) codes, and drops 3; 126 rows repeat a code with modifier QW for CLIA-waived testing.
The October 2026 file in numbers
- Code and modifier rows
- 2,243
- 2,117 distinct codes
- National payment amounts
- 2,125
- 118 rows priced by the contractor
- CLIA-waived (QW) rows
- 126
- 126 at the same amount as the base code
- PLA codes
- 617
- four digits and U
- HCPCS Level II lab codes
- 42
- G, P, Q and U codes
- Median national amount
- $35.09
- $2.17 to $12,000.00
Each row of the file carries the year, the code, an optional modifier, the date the amount took effect, a pricing indicator and the payment rate. The indicator is N when CMS sets a national payment amount that every Medicare Administrative Contractor pays, and L when the code is priced locally by the Medicare Administrative Contractor; locally priced rows show a rate of zero in the file. Most rows took effect on January 1, 2026; 88 rows carry a later date (1 on 2026-03-24, 17 on 2026-04-01, 1 on 2026-05-15, 30 on 2026-07-01, 39 on 2026-10-01), the quarterly additions CMS makes as new codes are created.
How Medicare pays a laboratory test
The CLFS is a single national schedule: unlike the physician fee schedule there are no geographic practice cost indices and no locality adjustment, so a test pays the same national amount in Manhattan and in rural Arkansas. Part B pays the lesser of the amount the laboratory bills and the fee schedule amount, and clinical diagnostic laboratory tests carry neither the Part B deductible nor coinsurance, so the amount in the file is what Medicare pays for a covered test. Since 2018 most national amounts have been set from the private payer rates that applicable laboratories report to CMS under the Protecting Access to Medicare Act of 2014 (section 1834A of the Social Security Act), using a weighted median of those rates for each code.
A laboratory test is paid from the CLFS only when it is billed on its own. The professional component of certain pathology services is a physician fee schedule service, tests furnished during an inpatient stay are bundled into the MS-DRG payment, and tests on a hospital outpatient claim are usually packaged into the OPPS payment for the visit or procedure (status indicator Q4 marks laboratory codes that are packaged unless they are the only services on the claim). The Medicare fee lookup returns the CLFS amount, the physician fee schedule row and the OPPS status indicator for a code side by side, so the three answers can be compared.
National amounts by code range
The base rows (without modifier QW) grouped by code range. Chemistry has the most codes (411, median $14.78), while the molecular and proprietary ranges carry the highest amounts: molecular pathology and genomic codes have a median of $274.83 and PLA codes $634.84, with 114 PLA codes still priced locally.
| Code range | Codes | Local | Median | Lowest to highest |
|---|---|---|---|---|
| Organ and disease panels80047-80081 | 10 | — | $11.98 | $7.01 to $74.86 |
| Drug testing and therapeutic drug levels80143-80377 | 57 | — | $16.59 | $6.61 to $62.14 |
| Evocative and suppression testing80400-80439 | 23 | — | $86.96 | $32.62 to $801.62 |
| Urinalysis81000-81099 | 10 | — | $3.56 | $2.17 to $29.98 |
| Molecular pathology, genomic sequencing and multianalyte assays81105-81599 | 307 | 1 | $274.83 | $35.00 to $12,000.00 |
| Chemistry82009-84999 | 411 | — | $14.78 | $3.28 to $128.92 |
| Hematology and coagulation85002-85999 | 96 | — | $9.79 | $2.37 to $80.46 |
| Immunology and transfusion medicine86000-86999 | 223 | — | $14.05 | $2.99 to $357.56 |
| Microbiology87003-87999 | 241 | 2 | $22.75 | $4.27 to $679.77 |
| Anatomic pathology, cytopathology and other laboratory procedures88000-89398 | 63 | — | $21.42 | $4.27 to $264.34 |
| Proprietary laboratory analyses (PLA codes, four digits and U)0001U-0999U | 617 | 114 | $634.84 | $4.48 to $8,500.00 |
| Multianalyte assays with algorithmic analyses (four digits and M)0001M-0999M | 14 | — | $736.20 | $79.00 to $3,489.63 |
| HCPCS Level II laboratory codesG, P, Q and U codes | 42 | 1 | $19.31 | $4.27 to $246.92 |
| Other codes outside the laboratory code ranges | 3 | — | $11.06 | $9.34 to $94.41 |
How the national amounts are spread
| National amount | Codes |
|---|---|
| $0 to under $10 | 283 |
| $10 to under $25 | 586 |
| $25 to under $50 | 240 |
| $50 to under $100 | 105 |
| $100 to under $250 | 212 |
| $250 to under $500 | 179 |
| $500 to under $1,000 | 179 |
| $1,000 and over | 215 |
HCPCS Level II laboratory codes on the CLFS
42 HCPCS Level II codes are priced on the laboratory schedule: Medicare screening tests such as G0103, G0328 and the HIV and hepatitis screening codes, cervical cytopathology in G0123-G0148 and P3000, definitive drug testing in G0480-G0483 and G0659, specimen collection codes G0471 and P9612, the older chemistry tests in P2028-P2038, microscopy in Q0111-Q0115, and U0001 and U0002 for COVID-19 testing. Descriptors are CMS's HCPCS Level II descriptors from the October 2026 file; codes with an indexed reference page link to it.
| Code | Descriptor | Rate | Pricing |
|---|---|---|---|
| G0027 | Semen analysis; presence and/or motility of sperm excluding huhner | $6.50 | N |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | $19.31 | N |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | $20.26 | N |
| G0143 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with manual screening and rescreening by cytotechnologist under physician supervision | $27.05 | N |
| G0144 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system, under physician supervision | $43.97 | N |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | $26.49 | N |
| G0147 | Screening cytopathology smears, cervical or vaginal, performed by automated system under physician supervision | $18.54 | N |
| G0148 | Screening cytopathology smears, cervical or vaginal, performed by automated system with manual rescreening | $31.94 | N |
| G0306 | Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count | $7.77 | N |
| G0307 | Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count) | $6.47 | N |
| G0327 | Colorectal cancer screening; blood-based biomarker | local | L |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneousAlso listed with QW (CLIA-waived) | $18.05 | N |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | $19.57 | N |
| G0433 | Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screeningAlso listed with QW (CLIA-waived) | $18.29 | N |
| G0435 | Infectious agent antibody detection by rapid antibody test, hiv-1 and/or hiv-2, screening | $11.98 | N |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | $11.34 | N |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s)Also listed with QW (CLIA-waived) | $46.35 | N |
| G0475 | Hiv antigen/antibody, combination assay, screeningAlso listed with QW (CLIA-waived) | $24.08 | N |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | $35.09 | N |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | $114.43 | N |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | $156.59 | N |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | $198.74 | N |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | $246.92 | N |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | $28.27 | N |
| G0567 | Infectious agent detection by nucleic acid (dna or rna); hepatitis c, screening, amplified probe techniqueAlso listed with QW (CLIA-waived) | $35.09 | N |
| G0659 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes | $62.14 | N |
| G9143 | Warfarin responsiveness testing by genetic technique using any method, any number of specimen(s) | $120.72 | N |
| P2028 | Cephalin floculation, blood | $4.95 | N |
| P2029 | Congo red, blood | $4.95 | N |
| P2031 | Hair analysis (excluding arsenic) | $4.95 | N |
| P2033 | Thymol turbidity, blood | $4.95 | N |
| P2038 | Mucoprotein, blood (seromucoid) (medical necessity procedure) | $4.95 | N |
| P3000 | Screening papanicolaou smear, cervical or vaginal, up to three smears, by technician under physician supervision | $18.54 | N |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | $9.34 | N |
| P9615 | Catheterization for collection of specimen(s) (multiple patients) | $9.34 | N |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | $18.54 | N |
| Q0112 | All potassium hydroxide (koh) preparations | $5.83 | N |
| Q0113 | Pinworm examinations | $4.27 | N |
| Q0114 | Fern test | $9.74 | N |
| Q0115 | Post-coital direct, qualitative examinations of vaginal or cervical mucous | $25.00 | N |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | $35.92 | N |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdcAlso listed with QW (CLIA-waived) | $51.31 | N |
The highest national amounts
The fifteen highest national amounts on the October file all belong to molecular, genomic, multianalyte or proprietary laboratory tests. They are CPT numbers, shown without descriptors; open one in the fee lookup to see its CLFS row with any QW variant and its OPPS status.
| Code | Code type | National amount | Effective |
|---|---|---|---|
| 81416 | CPT number | $12,000.00 | 2026-01-01 |
| 0315U | PLA (CPT number) | $8,500.00 | 2026-01-01 |
| 0211U | PLA (CPT number) | $8,455.00 | 2026-01-01 |
| 81552 | CPT number | $7,776.00 | 2026-01-01 |
| 0094U | PLA (CPT number) | $7,582.20 | 2026-01-01 |
| 0426U | PLA (CPT number) | $7,582.20 | 2026-01-01 |
| 0582U | PLA (CPT number) | $7,582.20 | 2026-01-01 |
| 81529 | CPT number | $7,193.00 | 2026-01-01 |
| 0267U | PLA (CPT number) | $6,739.33 | 2026-01-01 |
| 0265U | PLA (CPT number) | $5,475.80 | 2026-01-01 |
| 0212U | PLA (CPT number) | $5,475.20 | 2026-01-01 |
| 0295U | PLA (CPT number) | $5,435.00 | 2026-01-01 |
| 81554 | CPT number | $5,409.60 | 2026-01-01 |
| 0214U | PLA (CPT number) | $5,224.60 | 2026-01-01 |
| 0335U | PLA (CPT number) | $5,224.60 | 2026-01-01 |
What changed from July to October 2026
Comparing the fourth-quarter file with the third-quarter file (26CLABQ3, 2,206 rows) row by row, 40 rows are new, 3 are gone and no rate on a row present in both files changed. 39 of the new rows take effect on October 1, 2026; 39 of them are priced locally until CMS sets a national amount, the rest carry an earlier effective date because CMS added them retroactively to the date the code became valid.
| Code | Code type | Modifier | Effective | Rate |
|---|---|---|---|---|
| 0442U | PLA (CPT number) | QW | 2026-03-24 | $41.38 |
| 0660U | PLA (CPT number) | — | 2026-10-01 | local |
| 0661U | PLA (CPT number) | — | 2026-10-01 | local |
| 0662U | PLA (CPT number) | — | 2026-10-01 | local |
| 0663U | PLA (CPT number) | — | 2026-10-01 | local |
| 0664U | PLA (CPT number) | — | 2026-10-01 | local |
| 0665U | PLA (CPT number) | — | 2026-10-01 | local |
| 0666U | PLA (CPT number) | — | 2026-10-01 | local |
| 0667U | PLA (CPT number) | — | 2026-10-01 | local |
| 0668U | PLA (CPT number) | — | 2026-10-01 | local |
| 0669U | PLA (CPT number) | — | 2026-10-01 | local |
| 0670U | PLA (CPT number) | — | 2026-10-01 | local |
| 0671U | PLA (CPT number) | — | 2026-10-01 | local |
| 0672U | PLA (CPT number) | — | 2026-10-01 | local |
| 0673U | PLA (CPT number) | — | 2026-10-01 | local |
| 0674U | PLA (CPT number) | — | 2026-10-01 | local |
| 0675U | PLA (CPT number) | — | 2026-10-01 | local |
| 0676U | PLA (CPT number) | — | 2026-10-01 | local |
| 0677U | PLA (CPT number) | — | 2026-10-01 | local |
| 0678U | PLA (CPT number) | — | 2026-10-01 | local |
| 0679U | PLA (CPT number) | — | 2026-10-01 | local |
| 0680U | PLA (CPT number) | — | 2026-10-01 | local |
| 0681U | PLA (CPT number) | — | 2026-10-01 | local |
| 0682U | PLA (CPT number) | — | 2026-10-01 | local |
| 0683U | PLA (CPT number) | — | 2026-10-01 | local |
| 0684U | PLA (CPT number) | — | 2026-10-01 | local |
| 0685U | PLA (CPT number) | — | 2026-10-01 | local |
| 0686U | PLA (CPT number) | — | 2026-10-01 | local |
| 0687U | PLA (CPT number) | — | 2026-10-01 | local |
| 0688U | PLA (CPT number) | — | 2026-10-01 | local |
| 0689U | PLA (CPT number) | — | 2026-10-01 | local |
| 0690U | PLA (CPT number) | — | 2026-10-01 | local |
| 0691U | PLA (CPT number) | — | 2026-10-01 | local |
| 0692U | PLA (CPT number) | — | 2026-10-01 | local |
| 0693U | PLA (CPT number) | — | 2026-10-01 | local |
| 0694U | PLA (CPT number) | — | 2026-10-01 | local |
| 0695U | PLA (CPT number) | — | 2026-10-01 | local |
| 0696U | PLA (CPT number) | — | 2026-10-01 | local |
| 0697U | PLA (CPT number) | — | 2026-10-01 | local |
| 0698U | PLA (CPT number) | — | 2026-10-01 | local |
No longer on the October file: 0556U ($142.63 in July), 0557U ($262.99 in July), 0585U ($2,919.60 in July).
Laboratory NCDs and their national amounts
The 23 laboratory national coverage determinations govern common tests through a national edit: the procedure codes each one names are paid only when the claim carries a diagnosis the NCD's ICD-10-CM list supports. 23 of them name codes with a national amount on this file. Each NCD page lists its procedure codes with these amounts and the covered and non-covered diagnosis codes.
Billing notes that change the amount
Modifier QW tells the contractor that a test on the CLIA-waived list was performed by a laboratory holding a certificate of waiver; without it, a waived laboratory's claim for that test is denied for CLIA reasons even though the amount is the same. Medically unlikely edits cap the units of many laboratory codes per day, and NCCI procedure-to-procedure edits bundle component tests into panels, so the MUE lookup and the NCCI checker answer the questions a lab line raises before it is priced. Coverage for tests outside the national laboratory NCDs is decided locally; the LCD lookup finds the contractor policies that list a code.
Hospital laboratories that bill on the 13x outpatient type of bill use the same CLFS amounts for tests that are not packaged, and the OPPS status indicator page explains when the Q4 conditional packaging applies. Other fee schedules on this site: the physician fee schedule for pathology interpretations and the fee schedules hub for the full map.
Where QuickIntell fits for laboratory claims
QuickRCM covers eligibility, claim readiness, denials and posting with configurable automation and human review, which is where a missing QW modifier, an unsupported diagnosis under a lab NCD or a unit limit is caught before the claim goes out.
Frequently asked questions
What is the Medicare Clinical Laboratory Fee Schedule?
The fee schedule Medicare Part B uses to pay clinical diagnostic laboratory tests. CMS publishes it quarterly; the fourth quarter 2026 file (26CLABQ4) has 2,117 codes, 2,075 of them CPT numbers (including 617 proprietary laboratory analyses codes and 14 multianalyte assay codes) and 42 HCPCS Level II codes. Since 2018 most national amounts are set from private payer rates that laboratories report to CMS under the Protecting Access to Medicare Act.
Do Medicare patients pay coinsurance for lab tests?
No. Clinical diagnostic laboratory tests paid under the CLFS carry no Part B deductible and no coinsurance, and Part B pays the lesser of the amount billed and the fee schedule amount. Laboratory services furnished as part of another payment, such as a hospital inpatient stay, are paid under that system instead.
What does indicator L mean in the CLFS file?
L means the code is priced locally: the Medicare Administrative Contractor sets the payment, and the file shows $0.00 for it. 118 rows carry L this quarter, 118 of them with a zero rate. N marks a national payment amount that every contractor pays.
What is modifier QW on the lab fee schedule?
QW identifies a test performed under a CLIA certificate of waiver. The 26CLABQ4 file lists 126 QW rows, and 126 of them carry the same amount as the code without the modifier, so the modifier marks a test run under a waiver rather than changing the amount.
How many lab codes were added to the CLFS in October 2026?
40 rows appear in the October file that were not in the July file (39 effective October 1, 2026), 3 rows were dropped, and no rate on a code present in both files changed.
Is specimen collection paid on the lab fee schedule?
Some collection services are. G0471, collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha), is on the 26CLABQ4 file at $11.34. Routine venipuncture is billed with its CPT number, which is also on the file.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-10. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Clinical Laboratory Fee Schedule public use file, 2026 fourth quarter (26CLABQ4)Version 26CLABQ4 (CY2026 Q4) · effective 2026-10-01 · file PUF_CLFS_CY2026_Q4V1.csvSHA-256 fcfec34526c44390…
- Clinical Laboratory Fee Schedule public use file, 2026 third quarter (26CLABQ3)Version 26CLABQ3 (CY2026 Q3) · effective 2026-07-01 · file PUF_CLFS_CY2026_Q3V1.csvSHA-256 f5a090789c40fe79…
- HCPCS Level II alpha-numeric file, October 2026Version October 2026 · effective 2026-10-01 · file HCPC2026_OCT_ANWEB_09232026.txtSHA-256 c25240c63108756d…
- Laboratory NCD ICD-10 code lists, October 2026Version October 2026 · effective 2026-10-01 · file 2026400-Initial-ICD10-NCD-Spreadsheet-20260601-508.xlsxSHA-256 ec4361dc65f63432…
Disclaimer
Operational reference compiled from the CMS Clinical Laboratory Fee Schedule public use files for July and October 2026. Amounts are Medicare national payment amounts; Medicare Advantage, Medicaid and commercial plans set their own rates. CPT, PLA and MAAA codes appear as bare numbers; CPT descriptors are copyright AMA and are not shown. Not legal, coding or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.